What is Glenmark Pharmaceuticals Ltd. Quarterly Revenue?

Glenmark Pharmaceuticals Ltd. Quarterly Revenue Glenmark Pharma Jun-2026 Quarterly Revenue is Rs 2,550 Cr which is growth of 3.5% YoY.

What is Glenmark Pharmaceuticals Ltd. Quarterly Net Profit?

Glenmark Pharmaceuticals Ltd. Quarterly Net Profit Glenmark Pharma Jun-2026 Quarterly Net Profit is Rs 736 Cr which is growth of 122.8% YoY.

What is Glenmark Pharmaceuticals Ltd. Annual Revenue?

Glenmark Pharmaceuticals Ltd. Annual Revenue Glenmark Pharma Mar-2026 Annual Revenue is Rs 9,212 Cr which is growth of -3.9% YoY.

What is Glenmark Pharmaceuticals Ltd. Annual Net Profit?

Glenmark Pharmaceuticals Ltd. Annual Net Profit Glenmark Pharma Mar-2026 Annual Net Profit is Rs -201 Cr which is growth of -112.5% YoY.

What is Glenmark Pharmaceuticals Ltd. Total Shareholders Fund?

Glenmark Pharmaceuticals Ltd. Total Shareholders Fund Glenmark Pharma Mar-2026 Total Shareholders Fund is Rs 24,150 Cr which is growth of -1.4% YoY.

What is Glenmark Pharmaceuticals Ltd. Total Assets?

Glenmark Pharmaceuticals Ltd. Total Assets Glenmark Pharma Mar-2026 Total Assets is Rs 29,485 Cr which is growth of 5.2% YoY.

What is Glenmark Pharmaceuticals Ltd. Book Value Per Share?

Glenmark Pharmaceuticals Ltd. Book Value Per Share Glenmark Pharma Mar-2026 Book Value Per Share is 856 Rs which is growth of -1.4% YoY.

What is Glenmark Pharmaceuticals Ltd. ROE?

Glenmark Pharmaceuticals Ltd. ROE Glenmark Pharma Mar-2026 ROE is -1% which is growth of 7.4% YoY.

What is Glenmark Pharmaceuticals Ltd. Cash From Operating Activity?

Glenmark Pharmaceuticals Ltd. Cash From Operating Activity Glenmark Pharma Mar-2026 Cash From Operating Activity is Rs 543 Cr which is growth of -7.7% YoY.

What is Glenmark Pharmaceuticals Ltd. Net Cash Flow?

Glenmark Pharmaceuticals Ltd. Net Cash Flow Glenmark Pharma Mar-2026 Net Cash Flow is Rs 160 Cr which is growth of 4045.8% YoY.

GLENMARK quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for GLENMARK share price target, revenues, EPS, net income and more

GLENMARK quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Glenmark Pharma Jun-2026 Quarterly Revenue is Rs 2,550 Cr which is growth of 3.5% YoY.
POSITIVE
Quarterly Net Profit Glenmark Pharma Jun-2026 Quarterly Net Profit is Rs 736 Cr which is growth of 122.8% YoY.

Glenmark Pharmaceuticals Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
TOTAL_SR_Q Total Rev. ⌄	2,550.4	2,454.5	2,469	1,824.4	2,464.3	2,097.9	2,380.5	2,719.2	2,385.2	2,934.5	1,623.9	2,279.6	2,193.7
SR_Q Operating Rev.	2,435	2,146.6	2,359.9	1,538.7	2,394.9	2,009.5	2,251.3	2,636.1	2,329.5	2,148.2	1,365.1	2,233.4	2,144.4
OI_Q Other Income	115.4	307.9	109.1	285.8	69.3	88.5	129.2	83.1	55.7	786.3	258.8	46.2	49.4
OEXPNS_Q Operating Exp.	1,821.7	2,115	1,864.2	1,716.7	1,666.8	1,669	1,757.4	1,857.5	1,698.4	1,650.8	1,549.4	1,762.6	1,659.4
OEXPNS_Q Operating Exp.	1,821.7	2,115	1,864.2	1,716.7	1,666.8	1,669	1,757.4	1,857.5	1,698.4	1,650.8	1,549.4	1,762.6	1,659.4
OP_Q Operating Profit	613.3	31.5	495.7	-178	728.2	340.5	493.9	778.6	631.1	497.5	-184.3	470.9	485
OPMPCT_Q Operating Profit Margin %	25.18%	1.47%	21.01%	-11.57%	30.40%	16.95%	21.94%	29.54%	27.09%	23.16%	-13.50%	21.08%	22.62%
DEP_Q Depr.	62.3	60.1	59.2	58.9	57.6	55.5	55.2	54.9	53.1	52.4	51.2	49.9	48.8
INT_Q Interest	23.2	17.9	22	23.4	15.5	13.1	8.5	11.8	15.4	83.4	73.6	58.2	61.9
PBT_Q Profit Before Tax	866.1	-107.4	346.5	-906.4	401.2	181.2	559.5	795.1	618.3	6,294.8	-75.5	389.4	392
TAX_Q Tax	130.5	-33.5	64.5	-167.2	70.9	33.4	145.7	200	164.6	1,681.2	-55.1	87	120.4
NP_Q Net Profit	735.6	-73.9	282.1	-739.2	330.2	147.8	413.8	595.1	453.7	4,613.7	-20.4	302.4	271.7
EPS_adj_Q EPS Adj. latest	26.1	-2.6	10	-26.2	11.7	5.2	14.7	21.1	16.1	163.5	-0.7	10.7	9.6
NP_TTM Net profit TTM	204.6	-200.8	20.9	152.6	1,486.8	1,610.4	6,076.3	5,642.1	5,349.4	5,167.3	416.1	867	987.8
EPS_TTM Basic EPS TTM	7.3	-7.1	0.7	5.4	52.7	57.1	215.3	199.9	189.6	183.1	14.8	30.7	35
earnings_transcripts Earnings Transcripts
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes		Notes	Notes	Notes	Notes	Notes	Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

GLENMARK competitor comparison and performance snapshot within industry

GLENMARK annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Annual Revenue Glenmark Pharma Mar-2026 Annual Revenue is Rs 9,212 Cr which is growth of -3.9% YoY.
NEGATIVE
Annual Net Profit Glenmark Pharma Mar-2026 Annual Net Profit is Rs -201 Cr which is growth of -112.5% YoY.

Glenmark Pharmaceuticals Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
SR_A Total Rev. Ann. ⌄	0%	3%	9,298.3	9,212.1	9,582.8	9,059.1	9,206.6	8,756.2	7,964.2	7,319.4	6,780.5	6,612.3	8,243.7	6,232.5
TotalOperatingRevenues_A Operating Rev. Ann.	0.9%	2.2%	8,480.2	8,440.1	9,226.4	7,891.1	8,220.7	8,141.6	7,567.9	6,712.6	6,304.9	6,431.9	8,095.5	6,115.2
OI_A Other Income Ann.	-7.8%	14.3%	818.1	772	356.4	1,168	985.9	614.6	396.2	606.8	475.6	180.4	148.2	117.3
OEXPNS_A Operating Exp. Ann.	2.9%	5.3%	7,517.7	7,362.7	6,982.2	6,649.5	6,747.9	6,453.4	5,677.6	5,408.4	4,977.4	5,084.4	5,196.9	4,349.9
OEXPNS_A Operating Exp. Ann.	2.9%	5.3%	7,517.7	7,362.7	6,982.2	6,649.5	6,747.9	6,453.4	5,677.6	5,408.4	4,977.4	5,084.4	5,196.9	4,349.9
OP_A Operating Profit Ann.	-9.9%	-10.6%	962.5	1,077.4	2,244.2	1,241.7	1,472.8	1,688.2	1,890.3	1,304.2	1,327.5	1,347.5	2,898.6	1,765.3
OPMPCT_A OPM Ann. %	-9.9%	-13.2%		11.70%	23.42%	13.71%	16.00%	19.28%	23.74%	17.82%	19.58%	20.38%	35.16%	28.32%
TotalExpenses_A Total Exp. Ann. ⌄	2.5%	4.7%		7,677.3	7,249.6	7,128.7	7,138.9	6,849.1	6,094.3	5,803.3	5,307.5	5,393.5	5,454.4	4,485.9
OtherExpenses_A Other Exp. Ann.	6.7%	9.2%	2,502.2	2,439.6	2,131.3	1,957	2,005.7	1,801.6	1,570.7	1,670.1	1,648.5	1,683.9	1,856.9	1,645
EmployeeBenefitExpenses_A Employee Exp. Ann.	10%	10.1%	1,836	1,790.4	1,603.5	1,434.8	1,346.5	1,193.2	1,107.4	1,072.3	970	1,021.9	914.5	766.3
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	-9.1%	-4.2%		1,849.4	2,600.6	2,409.7	2,458.7	2,302.9	2,286.6	1,911	1,803.1	1,527.9	3,046.9	1,882.6
EBIDTPCT_A EBITDA Ann. margin %	-9.1%	-6.9%		20.08%	27.14%	26.60%	26.71%	26.30%	28.71%	26.11%	26.59%	23.11%	36.96%	30.21%
INT_A Interest Ann.	-27.5%	-21.6%	86.5	78.7	48.7	277.1	206.8	236	265.9	256.4	223.8	190.9	152.6	36.2
DEP_A Depr.	8.6%	9.4%	240.6	235.9	218.6	202.2	184.2	159.7	150.8	138.5	106.3	118.2	104.9	99.8
PBT_A PBT Ann.	-	-	198.9	-266.1	2,154	7,000.8	1,571.9	2,337.5	1,943.8	1,534.6	1,818.2	1,218.8	2,552.9	1,746.5
TAX_A Tax Ann.	-	-	-5.7	-65.3	543.7	1,833.5	363.1	339.7	294.3	180.1	329.9	204.5	412.3	262.3
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	-	-		-200.8	1,610.4	5,167.3	1,208.8	1,997.8	1,649.5	1,354.6	1,488.3	1,014.4	2,140.6	1,484.3
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	-	-	204.6	-200.8	1,610.4	5,167.3	1,208.8	1,997.8	1,649.5	1,354.6	1,622.1	1,014.4	2,140.6	1,484.3
NETPCT_A NPM Ann. %	-	-		-2.37%	17.45%	65.48%	14.70%	24.53%	21.79%	20.17%	25.72%	15.77%	26.44%	24.27%
EPS_adj_A EPS Adj. latest Ann.	-	-		-7.1	57.1	183.1	42.8	70.8	58.4	48	57.5	35.9	75.9	52.6
result_notes Result Notes				Notes		Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

-3.9%

2Y CAGR

0.8%

3Y CAGR

5Y CAGR

7Y CAGR

4.5%

10Y CAGR

Total Revenue Annual is falling faster than historical averages.

Operating Exp. Ann.

1Y CHG

5.4%

2Y CAGR

5.2%

3Y CAGR

2.9%

5Y CAGR

5.3%

7Y CAGR

5.8%

10Y CAGR

5.4%

Operating Expenses Annual Cr growth is stable compared to historical averages.

GLENMARK balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Total Shareholders Fund Glenmark Pharma Mar-2026 Total Shareholders Fund is Rs 24,150 Cr which is growth of -1.4% YoY.
POSITIVE
Total Assets Glenmark Pharma Mar-2026 Total Assets is Rs 29,485 Cr which is growth of 5.2% YoY.

Glenmark Pharmaceuticals Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	10.5%	10.3%	24,150.3	24,504	22,970.6	17,877.5	16,738.6	14,809.5	13,226.3	11,942.1	10,391.4	9,436.6	7,366
EQCAP_A Equity Share Capital Ann.	0%	0%	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2
TotalShareCapital_A Total Share Capital Ann.	0%	0%	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2
ReservesAndSurplus_A Reserves Plus Surplus Ann.	10.6%	10.3%	24,122.1	24,475.7	22,939.9	17,849.3	16,710.4	14,781.3	13,198.1	11,913.9	10,363.2	9,408.4	7,337.8
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	10.6%	10.3%	24,122.1	24,475.7	22,939.9	17,849.3	16,710.4	14,781.3	13,198.1	11,913.9	10,363.2	9,408.4	7,337.8
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	-18.4%	-12.8%	1,665.8	283.4	154.4	3,066.7	2,734.8	3,304.7	3,336.8	2,920	2,688.6	2,591.8	4.7
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	-	-		58.3
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	54.2%	50.6%	1,489.2	225.2	154.4	405.9	163.1	192.1	205.7	88.5	2.6	2.4	4.7
CL_A Total Current Liabilities Ann. ⌄	0.2%	7.9%	3,669	3,245.9	4,289.4	3,641.8	3,441.1	2,503.4	2,388.5	2,280.7	2,184.8	1,972.2	2,742.4
TradePayables_A Trade Payables Ann.	9.5%	11.1%	2,746	2,122.7	2,700.4	2,093.1	1,938.8	1,622.7	1,585.1	1,667.7	1,555	1,467.1	1,626
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-18.1%	15.2%	524.5	298.6	816.7	956.1	304.6	258.4	258.5	224.6	256.5	276.5	299.8
ShortTermProvisions_A ST Provisions Ann.	55.7%	27.4%	366.3	125.8	115	97	99.1	109.3	102.4	85.3	78.4	41.4	29.2
TL_A Total Capital Plus Liabilities Ann.	6.2%	7.4%	29,485.2	28,033.3	27,414.4	24,585.9	22,914.5	20,617.5	18,951.6	17,142.7	15,264.9	14,000.6	10,113
FixedAssets_A Fixed Assets Ann. ⌄	4.5%	3.4%	2,187.2	2,133.7	1,953.9	1,918.3	1,861.4	1,853.9	1,812	1,699.7	2,118.8	1,867	1,714.1
TangibleAssets_A Tangible Assets Ann.	7.5%	4.4%	1,848.7	1,785.2	1,538.6	1,488.7	1,468.5	1,490.3	1,468.8	1,308.2	1,576.7	1,470.5	1,321.9
IntangibleAssets_A Intangible Assets Ann.	-11.3%	-5%	179.3	194	217.7	257.3	283.8	232.2	143.1	105.3	122.5	125.9	116.1
CapitalWorkInProgress_A Capital Work In Progress Ann.	-24.9%	-6.3%	67.4	121.3	175.5	159.1	101.2	93.3	152.5	209.2	354	235.1	260.9
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	5%	8.3%	23,390.1	23,255.6	22,732.9	20,200.8	18,511.6	15,708.4	14,527.7	12,001.5	9,389.6	8,049.7	5,485.1
NonCurrentInvestments_A Non Current Investments Ann.	13.7%	16.8%	15,202.2	15,194.9	12,964.8	10,334	8,559.4	6,990	4,713.9	3,268.8	3,212.7	1,866.7	1,858.4
DeferredTaxAssets_A Deferred Tax Assets Ann.	-81.5%	-62.9%	6		165.9	946.8	923.3	853.3	804.7	712.1	660.6	594.1	401.2
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	-6.7%	-1.2%	5,582.1	5,754.3	7,505.7	6,874.1	7,078.6	5,930.7	7,115.6	6,263.9	3,302.9	3,642.7	1,447.3
OtherNonCurrentAssets_A Other Non Current Assets Ann.	47.9%	38.6%	412.5	172.7	142.7	127.6	88.9	80.6	81.5	57.1	94.7	79.2	64.1
CA_A Total Current Assets Ann. ⌄	11.6%	4.4%	6,095.1	4,777.7	4,681.5	4,385.2	4,402.9	4,909.1	4,423.9	5,141.2	5,875.3	5,950.8	4,627.9
CurrentInvestments_A Current Investments Ann.	-	-
TradeReceivables_A Trade Receivables Ann.	9.7%	5.8%	3,305.6	2,550.2	2,484.5	2,505.7	2,678.3	2,488.8	1,835.2	2,087.1	3,828.9	3,879.4	3,057.7
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	46.2%	79.3%	293.2	132.7	129.2	93.8	29.6	15.8	88.3	256.5	177.4	252.2	74.2
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	-	-
OtherCurrentAssets_A Other Current Assets Ann.	20.2%	-6%	1,208.3	725.5	925.2	695.5	743.3	1,642.2	1,662.9	1,886.3	757.8	674.2	528
TA_A Total Assets Ann.	6.2%	7.4%	29,485.2	28,033.3	27,414.4	24,585.9	22,914.5	20,617.5	18,951.6	17,142.7	15,264.9	14,000.6	10,113
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	-5.7%	-3.9%	3,286.1	4,308.3	2,658.5	3,923	3,699.7	4,013	4,663.3	3,894.1	5,216.1	4,317.1	4,939.6
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	0%	0%	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	13.7%	16.8%	15,202.1	15,194.8	12,219.6	10,332.5	8,557.9	6,989.9	4,713.9	3,268.7	3,212.7	1,866.6	1,858.3
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

5.2%

2Y CAGR

3.7%

3Y CAGR

6.2%

5Y CAGR

7.4%

7Y CAGR

8.1%

10Y CAGR

11.3%

Total Assets Annual growth is lower than historical averages.

Total Current Liabilities Ann.

1Y CHG

13%

2Y CAGR

-7.5%

3Y CAGR

0.2%

5Y CAGR

7.9%

7Y CAGR

10Y CAGR

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

-1.4%

2Y CAGR

2.5%

3Y CAGR

10.5%

5Y CAGR

10.3%

7Y CAGR

10.6%

10Y CAGR

12.6%

Total ShareHolders Funds Annual is falling faster than historical averages.

GLENMARK ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share Glenmark Pharma Mar-2026 Book Value Per Share is 856 Rs which is growth of -1.4% YoY.
POSITIVE
ROE Glenmark Pharma Mar-2026 ROE is -1% which is growth of 7.4% YoY.

Glenmark Pharmaceuticals Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
BVSH_A BVSH Ann.	10.5%	10.3%	855.8	868.4	814.1	633.6	593.2	524.8	468.7	423.2	368.3	334.4	261.1
ROA_A RoA Ann. %	-	-	-0.68%	5.74%	18.84%	4.91%	8.71%	8.00%	7.14%	9.46%	6.64%	15.28%	14.67%
ROE_A ROE Ann. %	-	-	-0.83%	6.57%	22.49%	6.76%	11.93%	11.13%	10.24%	13.58%	9.76%	22.68%	20.15%
ROCE_A ROCE Ann. %	-16.8%	-11.9%	6.25%	9.60%	9.54%	10.86%	11.00%	11.79%	10.70%	11.41%	10.77%	24.45%	24.18%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	-9.8%	-6.2%	21.91%	28.18%	30.53%	29.90%	28.28%	30.21%	28.46%	28.59%	23.75%	37.63%	30.78%
PBITMargin_A EBIT Ann. Margin %	-11.6%	-7.5%	19.11%	25.81%	27.97%	27.66%	26.32%	28.22%	26.40%	26.91%	21.91%	36.34%	29.15%
PBTMargin_A PBT Ann. Margin %	-	-	-3.15%	23.34%	88.71%	19.12%	28.70%	25.68%	22.86%	28.83%	18.94%	31.53%	28.56%
NETPCT_A NPM Ann. %	-	-	-2.37%	17.45%	65.48%	14.70%	24.53%	21.79%	20.17%	25.72%	15.77%	26.44%	24.27%
ASETTO_A Asset Turnover Ann. %	-9.1%	-5.6%	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.7	0.7
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	12.3%	-3.2%	1.7	1.5	1.1	1.2	1.3	2	1.9	2.3	2.7	3	1.7
QuickRatio_A Quick Ratio Ann.	13%	-5.2%	1.3	1.1	0.8	0.9	1	1.7	1.5	1.9	2.2	2.4	1.3
DividendPayoutNP_A Dividend Payout to NP Ann.	-	-	-0.7	0	0	0.1	0	0	0	0	0.1	0	0
EarningRetention_A Earning Retention Ann. %	21.8%	12.2%	170.27%	95.62%	98.64%	94.17%	96.47%	95.73%	94.98%	95.81%	93.31%	96.83%	95.43%
CashEarningRetention_A Cash Earning Retention Ann. %	-	-	-302.11%	96.15%	98.69%	94.94%	96.74%	96.09%	95.45%	96.07%	94.01%	96.98%	95.72%
CashEarningRetention_A Cash Earning Retention Ann. %	-	-	-302.11%	96.15%	98.69%	94.94%	96.74%	96.09%	95.45%	96.07%	94.01%	96.98%	95.72%
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	54.7%	29.1%	59,940.8	44,024.8	27,545.9	16,183.5	16,118.3	16,718	9,299.6	21,093.5	17,678.3	26,727.5	23,125.1
EVPerNetSales_A EV Per Net Sales Ann.	52.5%	26.4%	7.1	4.8	3.5	2	2	2.2	1.4	3.4	2.8	3.3	3.8
PBV_A Price To Book Value Adjusted	-9.5%	-9.3%	2.93	2.95	3.08	3.95	4.22	4.77	5.34	5.92	6.8	7.49	9.59
EVPerEBITDA_A EV Per EBITDA Ann.	70%	34.7%	32.4	16.9	11.4	6.6	7	7.3	4.9	11.7	11.6	8.8	12.3
MarketCapPerSales_A Market Cap Per Sales Ann.	64.3%	33.1%	7.1	4.7	3.4	1.6	1.5	1.7	0.9	2.9	2.3	3	3.7
RetentionRatios_A Retention Ratio Ann. %	21.8%	12.2%	170.27%	95.61%	98.63%	94.16%	96.46%	95.72%	94.97%	95.80%	93.30%	96.82%	95.42%
EYield_A Earnings Yield Ann.	-	-		0	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1
DEBT_CE_A Total Debt to Total Equity Ann.	-	-		0	0	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.1

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Current Ratio Ann.

1Y CHG

13.3%

2Y CAGR

24.3%

3Y CAGR

12.3%

5Y CAGR

-3.2%

7Y CAGR

-4.2%

Current Ratio Annual growth is higher than historical averages.

GLENMARK cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Glenmark Pharma Mar-2026 Cash From Operating Activity is Rs 543 Cr which is growth of -7.7% YoY.
POSITIVE
Net Cash Flow Glenmark Pharma Mar-2026 Net Cash Flow is Rs 160 Cr which is growth of 4045.8% YoY.

Glenmark Pharmaceuticals Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
CFO_A Cash from Operating Act. Ann. ⌄	-28.3%	-15.3%	543.3	588.8	-495.5	1,474.1	1,216.1	1,243.4	1,579.1	2,489.6	1,123.7	877.7	354.8
PBT_A PBT Ann.	-	-	-266.1	2,154	7,000.8	1,571.9	2,337.5	1,943.8	1,534.6	1,818.2	1,218.8	2,552.9	1,746.5
INT_A Interest Ann.	-27.5%	-21.6%	78.7	48.7	277.1	206.8	236	265.9	256.4	223.8	190.9	152.6	36.2
TAX_A Tax Ann.	-	-	-65.3	543.7	1,833.5	363.1	339.7	294.3	180.1	329.9	204.5	412.3	262.3
CFI_A Cash from Investing Act. Ann.	-	-	569.2	-489.5	3,197.2	-431.5	-896.9	-1,235.2	-1,607.4	-2,255.6	-1,137.1	-2,580.3	-1,545.6
CFA_A Cash from Financing Act. Ann.	-	-	-952.1	-95.4	-2,666.5	-978.5	-305.1	-80.8	-139.4	-155.1	-61.6	1,879.4	1,222.6
NCF_A Net Cash Flow Ann. ⌄	35.8%	-	160.4	3.9	35.3	64.1	14	-72.6	-167.7	78.9	-75	176.8	31.7
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	66.1%	8.5%	131.5	128	92.7	28.7	14.7	87.3	255	176.1	250.9	74.2	42
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	46.6%	81.8%	291.8	131.5	128	92.7	28.7	14.7	87.3	255	176.1	250.9	74.2

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

-7.7%

3Y CAGR

-28.3%

5Y CAGR

-15.3%

7Y CAGR

-19.5%

10Y CAGR

4.4%

Cash from Operating Activity Annual is falling slower than historical averages.

Cash from Investing Act. Ann.

2Y CAGR

-57.8%

Cash from Investing Activity Annual growth is higher than historical averages.

GLENMARK investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents

GLENMARK quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

GLENMARK - Forecaster

Forecaster Analyst Estimates for GLENMARK share price target, revenues, EPS, net income and more